Roman Liebe

Roman Liebe

Auto-generated profile, based on publicly available information

Roman Liebe

Department of Medicine II, Saarland University Medical Center, Saarland University, Homburg, Germany

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Journal of Hepatology
Verified
Journal Article
Open access
RLRoman Liebe
Roman Liebe
Irene EspositoIrene Esposito
Irene Esposito
HBHans H. Bock
Hans H. Bock
SDStephan Vom Dahl
Stephan Vom Dahl
JSJan Stindt
Jan Stindt
VKVerena Keitel
Verena Keitel
The term non-alcoholic fatty liver disease (NAFLD) was originally coined to describe hepatic fat deposition as part of the metabolic syndrome. However, a variety of rare hereditary liver and metabolic diseases, intestinal diseases, endocrine disorders and drugs may underlie, mimic, or aggravate NAFLD. In contrast to primary NAFLD, therapeutic interventions are available for many secondary causes of NAFLD. Accordingly, secondary causes of fatty liver disease should be considered during the diagnostic workup of patients with fatty liver disease, and treatment of the underlying disease should be started to halt disease progression. Common genetic variants in several genes involved in lipid handling and metabolism modulate the risk of progression from steatosis to fibrosis, cirrhosis and hepatocellular carcinoma development in NAFLD, alcohol-related liver disease and viral hepatitis. Hence, we speculate that genotyping of common risk variants for liver disease progression may be equally useful to gauge the likelihood of developing advanced liver disease in patients with secondary fatty liver disease.

1 July 2015 in Journal of Hepatology
Verified
Journal Article
Closed access
HLHai Li
Hai Li
QXQiang Xia
Qiang Xia
BZBo Zeng
Bo Zeng
SLShu-Ting Li
Shu-Ting Li
HLHeng Liu
Heng Liu
HWHonglei Weng
Honglei Weng

16 June 2015 in Frontiers in Physiology
Verified
Journal Article
Open access
PDF file
HWHonglei Weng
Honglei Weng
XCXiaobo Cai
Xiaobo Cai
XYXiaodong Yuan
Xiaodong Yuan
RLRoman Liebe
Roman Liebe
SDSteven Dooley
Steven Dooley
TWTai-Ling Wang
Tai-Ling Wang
Massive hepatic necrosis is a key event underlying acute liver failure, a serious clinical syndrome with high mortality. Massive hepatic necrosis in acute liver failure has unique pathophysiological characteristics including extremely rapid parenchymal cell death and removal. On the other hand, massive necrosis rapidly induces the activation of liver progenitor cells, the so-called “second pathway of liver regeneration”. The final clinical outcome of acute liver failure depends on whether liver progenitor cell-mediated regeneration can efficiently restore parenchymal mass and function within a short time. This review summarizes the current knowledge regarding massive hepatic necrosis and liver progenitor cell-mediated regeneration in patients with acute liver failure, the two sides of one coin.

13 November 2018 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
XYXiaodong Yuan
Xiaodong Yuan
JLJun Li
Jun Li
CCCédric Coulouarn
Cédric Coulouarn
TLTao Lin
Tao Lin
LSLaurent Sulpice
Laurent Sulpice
HWHonglei Weng
Honglei Weng
Sex-determining region Y-box (SRY-box) containing gene 9 (SOX9) expression confers cancer stem cell features. However, SOX9 function in intrahepatic cholangiocarcinoma (iCCA) is unknown. This study investigated the effects and underlying mechanisms of SOX9 in iCCA. SOX9 expression in 59 iCCA patients was examined by immunohistochemistry. The association between SOX9 expression and clinical outcome was evaluated. Gene signature and biological functions of SOX9 in iCCA were examined in vitro. iCCA patients with high SOX9 expression had shorter survival time than those with low SOX9. In patients receiving chemotherapy, median survival time in patients with low and high levels of SOX9 were 62 and 22 months, respectively. In vitro, gemcitabine increased SOX9 expression in iCCA cells. When SOX9 was knocked down, gemcitabine-induced apoptosis was markedly increased. Silencing SOX9 significantly inhibited gemcitabine-induced phosphorylation of checkpoint kinase 1, a key cell cycle checkpoint protein that coordinates the DNA damage response and inhibited the expression of multidrug resistance genes. Microarray analyses showed that SOX9 knockdown in CCA cells altered gene signatures associated with multidrug resistance and p53 signalling. SOX9 governs the response of CCA cells to chemotherapy. SOX9 is a biomarker to select iCCA patients eligible for efficient chemotherapy.

1 June 2015 in OncoImmunology
Verified
Journal Article
Open access
CYChang-Hong Yi
Chang-Hong Yi
HWHong-Lei Weng
Hong-Lei Weng
FZFei-Guo Zhou
Fei-Guo Zhou
MFMeng Fang
Meng Fang
JJJun Ji
Jun Ji
CGChun-Fang Gao
Chun-Fang Gao
Immunoglubulin G (IgG) and its abnormal glycosylations are associated with carcinogenesis. The present study investigates the relationship between cancer-derived IgG and clinicopathological characteristics in hepatocellular carcinoma (HCC) and assesses the value of serum N-glycosylated IgG in diagnosing and monitoring hepatitis B virus (HBV)-related HCC. Tissue microarray analysis of 90 HCC tissues showed that HCC patients with IgG immunopositivity had higher levels of core-fucosylated α fetoprotein (AFP-L3), larger tumors, and a higher incidence of portal vein tumor thrombus. HCC-derived IgG stimulated the growth of liver cancer cells in vitro. HCC patients presented a significantly increased fraction of Lens culinaris agglutinin binding IgG (core-fucosylated IgG, IgG-L3) among total serum IgG. The clinical diagnostic performance of serum IgG-L3% was evaluated in 3 case-control studies (1 training set and 2 validation cohorts), including 293 patients with HCC, 131 with liver cirrhosis, 132 HBV carriers, and 151 healthy controls. IgG-L3% had better general diagnostic performance than AFP in the training set and validation cohort 1 (accuracy: 81.33–85.11% versus 63.33–78.61%). In validation cohort 2, where we aimed to assess the efficiency of IgG-L3% in patients with AFP-negative HCC, the diagnostic accuracy of IgG-L3% was 72.54–73.60%. Finally, a longitudinal evaluation based on 31 HCC patients demonstrated that IgG-L3% decreased in 24 patients after curative surgery. The remaining 7 patients showed elevated IgG-L3% and post-operative recurrence. HCC patients with higher IgG-L3% had poor survival during a 3-year follow up. We conclude that HCC-derived IgG is correlated with progressive behavior of HCC. Therefore, elevated core-fucosylated IgG is a new diagnostic and prognostic marker in HBV-related HCC.

20 February 2022 in Liver International
Verified
Journal Article
Open access
PDF file
EPEva Doreen Pfister
Eva Doreen Pfister
CDCarola Dröge
Carola Dröge
RLRoman Liebe
Roman Liebe
ASAmelie Stalke
Amelie Stalke
NBNicole Buhl
Nicole Buhl
VKVerena Keitel
Verena Keitel
Background and Aims: Progressive familial intrahepatic cholestasis (PFIC) is a collective term for a heterogenous group of rare, inherited cholestasis syndromes. The number of genes underlying the clinical PFIC phenotype is still increasing. While progressive liver disease and its sequelae such as portal hypertension, pruritus and hepatocellular carcinoma determine transplant‐free survival, extrahepatic manifestations may cause relevant morbidity.Methods: We performed a literature search for extrahepatic manifestations of PFIC associated with pathogenic gene variants in ATP8B1, ABCB11, ABCB4, TJP2, NR1H4 and MYO5B. To illustrate the extrahepatic symptoms described in the literature, PFIC cases from our centres were revisited.Results: Extrahepatic symptoms are common in PFIC subtypes, where the affected gene is expressed at high levels in other tissues. While most liver‐associated complications resolve after successful orthotopic liver transplantation (OLT), some extrahepatic symptoms show no response or even worsen after OLT.Conclusion: The spectrum of extrahepatic manifestations in PFIC highlights essential, non‐redundant roles of the affected genes in other organs. Extrahepatic features contribute towards low health‐related quality of life (HRQOL) and morbidity in PFIC. While OLT is often the only remaining, curative treatment, potential extrahepatic manifestations need to be carefully monitored and addressed.